Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Dopamine | HCID 681 | — |
| Reactant | Tyramine | HCID 5610 | — |
| Reactant | (S)-[(2R,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol | HCID 5953 | — |
| Reactant | 1-((3-Hydroxy-4-methoxyphenyl)methyl)-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol | HCID 10233 | — |
| Reactant | Codeine | HCID 5284371 | — |
| Product | Morphine | HCID 5288826 | — |
Reaction Steps
To examine the tyramine to dopamine step, dopamine (DA) levels in ganglia and hemolymph were examined before and after tyramine addition followed by CYP2D6 inhibition by quinidine. Tyramine injection significantly increased ganglionic (4.98±0.27 μg/g to 9.17±1.21 μg/g wet weight; P<0.01) and hemolymph (10.13±1.24 μg/mL to 16.47±1.28 μg/mL, P<0.05) DA levels (FIGS. 19 and 20). The ganglionic and hemolymph DA level increases were blocked by quinidine exposure, demonstrating that the CYP2D6 enzyme was mediating this step. Ganglia were also exposed to THP, reticuline, DA, or codeine. Each resulted in significantly enhanced morphine levels, a phenomenon that was also significantly blocked by quinidine exposure, again demonstrating a role for CYP2D6 in the second part of the morphine biosynthetic pathway (FIGS. 15 and 20).
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US08481559B2 |
|---|
| Source dataset | uspto-grants-2013_07 |
|---|
| ORD ID | ord-eae22b0c7c294073beeb048fda45eec6 |
|---|
| Source note | uspto-grants-2013_07 |
|---|
